welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
study id #: NCT00140894
condition: Adenomatous Polyposis Coli
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
Drug: Comparator: placebo / Duration of Treatment: 24 weeks
start date: August 6, 2002
estimated completion: Not Available
last updated: September 20, 2019
phase of development: Phase 4
size / enrollment: 62
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- Number and average size of rectal polyps
- Safety and tolerability
- Number and average size of duodenal polyps
- Proportions of patients with improved overall colon rating
- Males or females at least 18 years of age with familial adenomatous polyposis.
expertly curated content related to this topic
Food Fit for a Baby J-pouch: The Early Post-Proctocolectomy Diet (the newest fad diet)https://www.youtube.com/watch?v=ms8o1BBN...
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Cl...IMPORTANCE: Patients with familial aden...
Colorectal Cancer GuidelinesThe American Society of Colon and Rectal...
Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis PatientsThe purpose of this study is to assess i...
Bonnies Diary March 08https://jtvcancersupport.com/embed/46053...
Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous PolyposisA Phase 2, randomized, double blind, pla...